Oramed Pharmaceuticals, Inc

-0.40 (-4.63%)
Products, Regulatory

Oramed Announces Positive Safety And Efficacy Data From Its Phase 2 Clinical Trial Of Ormd-0801

Published: 11/17/2022 22:33 GMT
Oramed Pharmaceuticals, Inc (ORMP) - Oramed Announces Additional Positive Safety and Efficacy Data From Its Phase 2 Clinical Trial of Ormd-0801 for Nash.
Oramed Pharmaceuticals Inc - Achieved Primary Endpoint of Safety and Tolerability in Participants With Type 2 Diabetes With Nash.
Oramed - Oral Insulin Candidate Shows Consistent Trends Across Key Secondary Endpoints With Reduction of Liver Fat, Liver Stiffness and Lipids.
Oramed Pharmaceuticals Inc - Primary Objective of Safety Met With No Serious Adverse Events.
Oramed Pharmaceuticals Inc - No Difference in Incidence Rate of Adverse Events Between Ormd-0801 and Placebo.